-
Security Type
-
Preferred Stock
-
Categories
-
Other
-
Min Investment
-
$1,003
-
Offering Date
-
December 16, 2019
-
Expected Close Date
-
June 29, 2020
-
Target Raise
-
$10.00K-$1.07M
-
Deal Notes
-
$4.25 per share
-
Valuation
-
$34,000,000
Company Description
BioCurity is a clinical stage biopharmaceutical company with a mission to materially improve and transform radiation therapy for cancer patients. Our proprietary technology is designed to prevent or mitigate damage to skin and normal internal tissue during radiation therapy without impairing the effectiveness of the radiation treatment on the patient’s cancer cells. The proposed drugs generated from BioCurity’s proprietary technology have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. The delivery system of the proposed drug includes a topical for the skin to prevent or mitigate skin damage (radiation dermatitis) and an intravenous (IV) formulation for internal tissue protection from radiation damage.
Key Deal Facts
Our technology has the potential to exponentially transform the radiation experience for cancer patients with a drug to prevent burns, blistering, permanent scarring and damage
Seven issued US patents with fully paid license for its technology in the US and International patents pending
Our team of experts brings over two decades of cancer treatment research, global biotechnology distribution and corporate governance
Management Team / Advisory Board Bios
Dr. Cheryl Baker
Chief Scientific Research Officer, and Director
Cheryl Baker has conducted cancer research for 20 plus years and published more than 45 peer-reviewed manuscripts, book chapters and articles. The proprietary nanoparticle technology supporting BioCurity’s mission was preclinically developed and tested by Cheryl Baker and her research and physician-scientist colleagues at an MD Anderson Cancer Center affiliate in collaboration with researchers at a State University.
Sam Merchant
Chairman of the Board of Directors
Sam has 30 Years of Experience, Co-Chairman, 3rd Generation Global Family Office, Extensive Success, Growing Companies Globally in Multiple Industry Sectors and Verticals including, Information-Technology, Healthcare, Bio-Technology, Pharmaceutical, R&D, Manufacturing, Distribution, Commercial Real Estate, Banking and Finance and other sectors. Capital Market Development for 100+ International and Domestic Companies.
Nancy Cass, Esq
Director
Nancy has 20 plus years securities law and transactional law experience with public and private emerging growth and middle market companies. Experienced in examining opportunities for financings, strategic partnerships and other transactions. Interacts with attorneys on transactions, review documents and conducts due diligence with added insight from her legal and securities training.
